Dactolisib (BEZ235, NVP-BEZ235)

Catalog No.S1009

Molecular Weight(MW): 469.55

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell.

Cited by 88 Publications

Nature, 2018, 560(7718):372-376

PubMed: 30046109 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nature, 2017, 728-732

PubMed: 28321130 ( click the link to review the publication )

Nature, 2014, 514(7524):628-32

PubMed: 25119024 ( click the link to review the publication )

Nature, 2012, 487(7408):505-9

PubMed: 22763448 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Blood, 2011, 118(14):3911-21

PubMed: 21821710 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(24):5499-5510

PubMed: 26272063 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926 ( click the link to review the publication )
Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255 ( click the link to review the publication )

Leukemia, 2017, 31(4):922-933

PubMed: 27686868 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683 ( click the link to review the publication )
Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880 ( click the link to review the publication )

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924 ( click the link to review the publication )

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062 ( click the link to review the publication )

Oncogene, 2012, 33(2):236-45

PubMed: 23246970 ( click the link to review the publication )

Cancer Lett, 2015, 359(1):47-56

PubMed: ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669 ( click the link to review the publication )
J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688 ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

FASEB J, 2014, fj.13-247924

PubMed: 24903273 ( click the link to review the publication )
Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679 ( click the link to review the publication )

Neoplasia, 2015, 17(1):16-31

PubMed: 25622896 ( click the link to review the publication )

Neoplasia, 2012, 14(1):34-43

PubMed: 22355272 ( click the link to review the publication )

J Mater Chem B, 2013, 5602-5610

PubMed: ( click the link to review the publication )

J Virol, 2014, 88(9):5152-64

PubMed: 24574393 ( click the link to review the publication )

J Virol, 2012, 86(8):4578-85

PubMed: 22345463 ( click the link to review the publication )

Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )
Apoptosis, 2014, 19(5):895-904

PubMed: 24652480 ( click the link to review the publication )

Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133 ( click the link to review the publication )

Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003 ( click the link to review the publication )

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )

Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )
J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108193

PubMed: 25247710 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59879

PubMed: 23533654 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931 ( click the link to review the publication )

Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318 ( click the link to review the publication )

Animal, 2016, 10(8):1319-27

PubMed: 26956906 ( click the link to review the publication )
Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

11 Customer Reviews

Level of phospho-proteins in RTK and PI3K–Akt–mTOR pathways in treated tumours, detected with western blot.

Nature, 2017, 728-732. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

A, ANOVA of IC50 values of the dual PI3K/mTOR inhibitor NVP-BEZ235 in 23 melanoma cell lines showing no significant difference in sensitivity to this compound in B-Raf mutant and Braf wild-type cells. B, decreases in pAkt and pP70S6K in a dose and time-dependent fashion in 2 melanoma cell lines treated with NVP-BEZ235. pP70S6K levels are undetectable at all concentrations and time points studied, whereas levels of pAkt start rising again after 4 hours of drug exposure in a dose-dependent fashion. C, clonogenic assays in 2 melanoma cell lines (YUVON and YUSIK) treated with NVP-BEZ235 at different concentrations. NVPBEZ235 was effective in inhibiting colony formation at low nanomolar concentrations.

Clin Cancer Res 2010 16, 6029-6039. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.
Relative kinase activities of p110α mutants and the inhibitory effect of PI3K inhibitors against hotspot mutants of p110α. A, recombinant FLAG-tagged PI3K p110α/p85α protein complex produced in 293T cells was immunoprecipitated , and the immunoprecipitates were used for the quantitative PI3K-HTRF assay (32).

B, effect of three PI3K inhibitors (ZSTK474, LY294002, and NVP-BEZ235) on the enzymatic activity of two hotspot mutants (E545K and H1047R) p110α compared with the wild-type. No striking difference was observed in the IC50 concentrations of these inhibitors between wild-type and mutant p110α.

Cancer Res 2010 70, 4982-4994. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

ZSTK474 and GDC-0941 selectively inhibit class I PI3K over mTOR. (A) Inhibition profiles of the selected five PI3K inhibitors for mTOR. Data shown are mean±SD (n = 3), representative of 2 or 3 independent experiments. (B) IC50 values of the PI3K inhibitors for mTOR. (C) Selectivity of each PI3K inhibitor for PI3Ka over mTOR. The selectivity index is expressed as the ratio of the IC50 value for mTOR over that for PI3Ka. The IC50 values of ZSTK474, NVP-BEZ235 and LY294002 for PI3Ka are 0.016, 0.007 and 0.6 μM, respectively, as reported previously by us.

Eur J Cancer 2010 46, 1111-1121. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.
Three-dimensional responses of MCF7/IGF-1R cells to TAM (1 μM), E2 and IGF-1. Compared to parental MCF7 cells (a), MCF7/IGF-1R cells (b) in three-dimensional (3D) culture formed bigger acini in response to IGF-1 stimulation and displayed significant TAM resistance when treated with TAM (1 μM) + E2 + IGF-1, which was removable by kinase inhibitors BMS-536924, U0126 and BEZ235 (c). Cells (10,000/well) were seeded in 96-well plates. Acini were formed on 100% Matrigel and cultured for 14 days in starving medium containing 2% Matrigel and 5% charcoal/dextran-stripped fetal bovine serum with the treatments as indicated. Concentrations used: TAM (1 μM), E2 (1 nM) and IGF-1 (100 ng/mL). Confocal image original magnification, × 20. Red, rhodamine phalloidin (actin). Blue, Hoechst blue stain. Results are representative of two individual experiments.

Breast Cancer Res 2011 13, R52. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

TAM (10 nM) agonistic behavior in MCF7/IGF-1R cells is not inhibited by phosphatidylinositol 3-kinase/Akt inhibitor BEZ235. (a) Inhibitory effects of kinase inhibitors BMS-536924, U0126 and BEZ235 on agonistic effect of TAM (10 nM) in the presence of IGF-1 (100 ng/mL). **P < 0.01. (b) Inhibitory effects of phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor BEZ235 at various dose ranges on IGF-1R signaling. (c) Agonistic behavior of TAM (10 nM) in response to BEZ235 kinase inhibitor. (-), no BEZ235. Results are representative of three independent experiments. Data are expressed as means ± SD.

Breast Cancer Res 2011 13:R52. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.
(B) The effects of AZD2014, BEZ235, lapatinib, LEE011, pazopanib on PI3K/AKT signaling in sarcoma PDC line were determined by immunoblotting analysis. Cells were treated with 1 μM of the indicated drugs for 72 h.

Transl Oncol, 2016, 9(3):197-202. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

The effects of LY294002, rapamycin and NVP-BEZ235 on activation of PI3K-Akt-mTOR pathway in hepatocytes. (a) The mRNA expression (PI3K, Akt, mTOR, raptor) by Real-Time PCR, (b) protein expression (PI3K, Akt, mTOR, S6K) by ELISA kits; (c) protein expression of S6K and P-S6K by western blotting. The different letters indicated significant differences (P <0.05). LY = LY294002; rapa = rapamycin; NVP = NVP-BEZ235.

Animal, 2016, 10(8):1319-27. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.
After starved in serum-free medium for 24h,breast cancer cells incubated with the indicated concentrations of BEZ235 for 3h,followed by 20-minute stimulation of 100ng/ml EGF.

Dr. Zhang of Tianjin Medical University. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

After starved in serum-free medium for 24h,breast cancer cells incubated with the indicated concentrations of BEZ235 for 3h,followed by 20-minute stimulation of 100ng/ml EGF.

Dr. Zhang of Tianjin Medical University. Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.
FIG. 4. Phospholipase A2 group 4A (PLA2G4A) expression was increased after BEZ235 treatment in basal-like xenografts. The bar graph shows the quantification of the immunoblots (mean±SD). PLA2G4A, Ethanolamine kinase 1 and 2 (ETNK1/2), Choline kinase alpha/beta (ChoKA/B), and β-actin protein expression were examined by immunoblotting of tissue samples after MRS experiments [control group (n= 5) and BEZ235-treated group (n=7)]. This demonstrated a higher expression of PLA2G4A protein ( P=0.005), but no changes in ETNK1 and ChoKA/B in samples from basal-like xenografts treated with BEZ235.

Dactolisib (BEZ235, NVP-BEZ235) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	View More
4 nM	5 nM	6 nM	7 nM	21 nM	View More

In vitro

BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. ^[1] BEZ235 is an mTORC1/2 catalytic inhibitor. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	MYjBcpRqdWmlcn;ibYFtKEG\|c3H5		NXnwWpRbOThiaB?=	MULEUXNQ	Ml7KRY51cXS{eYDhco9{d22jbDDhZ5Rqfmm2eTD3bZRpKEWFNUCgc4YhOC5yMEK1JO69VQ>?	NUjDRVZPOjR6MEW5OFY>
MCF7	Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWeyc24yOC5yMT2xNFAh\|ryP	MVu0PEBp	MoHPSG1UVw>?	M{P6UWlEPTB;MD63N{DPxE1?	NI\ZPXczOzh5MUmwOC=>
HCT116	NWDWRXFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLQNE4xOS1zMECg{txO	MYq0PEBp	NW\rOYp{TE2VTx?=	Mo[1TWM2OD1zLkG2JO69VQ>?	M3S1V\|I{QDdzOUC0
U87MG	M{S0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXi1T3RxOC5yMT2xNFAh\|ryP	MWO0PEBp	NXSye4FLTE2VTx?=	Mm\mTWM2OD1zLkOyJO69VQ>?	NFPYOGIzOzh5MUmwOC=>
HBC4	MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfFNIt[OC5yMT2xNFAh\|ryP	NXXCRlYyPDhiaB?=		MXTMc4chT0l3ME2tPE43OSCP	M1\hfVIzOzN4MkS2
BSY1	NUDBVYllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvuNE4xOS1zMECg{txO	MV20PEBp		NWDGcmlKVG:pIFfJOVA:NThwNEigUS=>	NUK2SGFoOjJ\|M{[yOFY>
HBC5	Mk\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHKTI0xNjBzLUGwNEDPxE1?	MX:0PEBp		NYPGRW91VG:pIFfJOVA:NTdwOEegUS=>	NHrJZpMzOjN\|NkK0Oi=>
MCF7	Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7sXJUxNjBzLUGwNEDPxE1?	NWLRZmloPDhiaB?=		NGW0dJVNd2diR1m1NF0uQC5zNjDN	NXLSeIZ6OjJ\|M{[yOFY>
MDA-MB-231	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPNNE4xOS1zMECg{txO	NHX6b5c1QCCq		NIm4cmZNd2diR1m1NF0uQC5yOTDN	MmXTNlI{OzZ{NE[=
U251	M37LWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljhNE4xOS1zMECg{txO	MoP6OFghcA>?		NITIbGZNd2diR1m1NF0uPy54NjDN	NXyzSWpJOjJ\|M{[yOFY>
SF268	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfSeotXOC5yMT2xNFAh\|ryP	NYfySJdvPDhiaB?=		NVLyXG9[VG:pIFfJOVA:NTdwOUKgUS=>	NInXNZEzOjN\|NkK0Oi=>
SF295	NEm0VFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;QdFAvODFvMUCwJO69VQ>?	NGfMW4M1QCCq		M3PjUGxw\yCJSUWwQU05NjNzIF2=	M{P4WVIzOzN4MkS2
SF539	M3HQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzxZXQxNjBzLUGwNEDPxE1?	MoHMOFghcA>?		M1y3TGxw\yCJSUWwQU05NjV7IF2=	NWq1Z2wyOjJ\|M{[yOFY>
SNB75	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\1dI1IOC5yMT2xNFAh\|ryP	NVjmPIlCPDhiaB?=		MWXMc4chT0l3ME2tPE42QCCP	MknqNlI{OzZ{NE[=
SNB78	NXfYfZdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjUNE4xOS1zMECg{txO	M{e2SlQ5KGh?		M33kcGxw\yCJSUWwQU05NjZ3IF2=	MVqyNlM{PjJ2Nh?=
HCC2998	Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TBNFAvODFvMUCwJO69VQ>?	NFHXO4I1QCCq		M4mzcmxw\yCJSUWwQU05NjB3IF2=	MkfVNlI{OzZ{NE[=
KM12	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLlXJFkOC5yMT2xNFAh\|ryP	MoHUOFghcA>?		NFnPUoVNd2diR1m1NF0uPy53NDDN	NW[zd4k6OjJ\|M{[yOFY>
HT-29	M{S1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\iUlAvODFvMUCwJO69VQ>?	Ml\wOFghcA>?		MmDrUI9oKEeLNUC9MVcvPzViTR?=	M{LiXVIzOzN4MkS2
HCT15	MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTOeYg{OC5yMT2xNFAh\|ryP	NIm2TGE1QCCq		MnfjUI9oKEeLNUC9MVgvODNiTR?=	MVeyNlM{PjJ2Nh?=
HCT116	NFG5eGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXGwMlAyNTFyMDFOwG0>	MXu0PEBp		NXPGVVNUVG:pIFfJOVA:NTdwNkGgUS=>	MVOyNlM{PjJ2Nh?=
NCI-H23	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVmwMlAyNTFyMDFOwG0>	MkHFOFghcA>?		MXTMc4chT0l3ME2tO{43PCCP	M1jiVVIzOzN4MkS2
NCI-H226	M3H2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVqwMlAyNTFyMDFOwG0>	M1nYOlQ5KGh?		NFPIXHpNd2diR1m1NF0uQC52NDDN	NFn3Oo0zOjN\|NkK0Oi=>
NCI-H522	NYX5dWU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3kNIgxNjBzLUGwNEDPxE1?	NVXM[mhzPDhiaB?=		MYjMc4chT0l3ME2tPE41PSCP	MVuyNlM{PjJ2Nh?=
NCI-H438	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nNWlAvODFvMUCwJO69VQ>?	MoDIOFghcA>?		MkCyUI9oKEeLNUC9MVgvOTFiTR?=	MlO4NlI{OzZ{NE[=
A549	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;IcFAvODFvMUCwJO69VQ>?	NFHsO3E1QCCq		M1fZ[mxw\yCJSUWwQU05NjB5IF2=	M{LuRVIzOzN4MkS2
DMS273	NIHMbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7wPWJxOC5yMT2xNFAh\|ryP	M4K2W\|Q5KGh?		MY\Mc4chT0l3ME2tO{45OCCP	NIHxenUzOjN\|NkK0Oi=>
DMS114	NF3SfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLqd4kxOC5yMT2xNFAh\|ryP	NXSxZWpxPDhiaB?=		MXXMc4chT0l3ME2tPE4{QSCP	MVyyNlM{PjJ2Nh?=
LOXIMVI	MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vPcFAvODFvMUCwJO69VQ>?	MYC0PEBp		M3PkO2xw\yCJSUWwQU05NjZ4IF2=	MVOyNlM{PjJ2Nh?=
OVCAR3	NGq5cmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzLNlQxNjBzLUGwNEDPxE1?	MXS0PEBp		MknmUI9oKEeLNUC9MVgvOTdiTR?=	NYi2VXdFOjJ\|M{[yOFY>
OVCAR4	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13USVAvODFvMUCwJO69VQ>?	M3vwfFQ5KGh?		NGDKcHJNd2diR1m1NF0uQC53ODDN	NXzTO2Z4OjJ\|M{[yOFY>
OVCAR5	NX[4R3JtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfyUXVsOC5yMT2xNFAh\|ryP	NGK2dIw1QCCq		NXXzdHJTVG:pIFfJOVA:NTdwNUegUS=>	MmHkNlI{OzZ{NE[=
OVCAR8	NFfjXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjpelIxNjBzLUGwNEDPxE1?	MnPKOFghcA>?		NFezXXdNd2diR1m1NF0uPy56NDDN	MXqyNlM{PjJ2Nh?=
SKOV3	MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU[wMlAyNTFyMDFOwG0>	MmfQOFghcA>?		MortUI9oKEeLNUC9MVgvPDFiTR?=	MmjyNlI{OzZ{NE[=
RXF631L	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF[1RYoxNjBzLUGwNEDPxE1?	MmTlOFghcA>?		MnHlUI9oKEeLNUC9MVgvOjFiTR?=	NULBd4I3OjJ\|M{[yOFY>
ACHN	M3PWXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVOwMlAyNTFyMDFOwG0>	NUXM[4c{PDhiaB?=		M2G0S2xw\yCJSUWwQU04Njl3IF2=	M2[1cVIzOzN4MkS2
St-4	M2DEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3sSHU4OC5yMT2xNFAh\|ryP	MYS0PEBp		M{HSdmxw\yCJSUWwQU04NjR5IF2=	NXT2VIU3OjJ\|M{[yOFY>
MKN1	NUjrVWpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUKwMlAyNTFyMDFOwG0>	NE\5S201QCCq		NG[4R4RNd2diR1m1NF0uQC52MTDN	NVfFWnpqOjJ\|M{[yOFY>
MKN7	MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUG0WXR7OC5yMT2xNFAh\|ryP	NEnXeow1QCCq		NGHaOVZNd2diR1m1NF0uPy54ODDN	MkDKNlI{OzZ{NE[=
MKN28	NWn0b2szT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;kdFAvODFvMUCwJO69VQ>?	M1flbVQ5KGh?		NW\Sb2VsVG:pIFfJOVA:NTdwMEegUS=>	MnS0NlI{OzZ{NE[=
MKN45	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHj3bHIxNjBzLUGwNEDPxE1?	NFi4SmI1QCCq		M2fwfWxw\yCJSUWwQU05NjN2IF2=	MWSyNlM{PjJ2Nh?=
MKN74	NFz5PJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjyVmYxNjBzLUGwNEDPxE1?	NWrkSY8zPDhiaB?=		NHfuZppNd2diR1m1NF0uPy52MjDN	MVKyNlM{PjJ2Nh?=
DU145	MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XqfFAvODFvMUCwJO69VQ>?	Mkj3OFghcA>?		NUnwN\|NyVG:pIFfJOVA:NThwMU[gUS=>	M3:5ZlIzOzN4MkS2
PC3	MonIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MViwMlAyNTFyMDFOwG0>	MmTTOFghcA>?		MnjUUI9oKEeLNUC9MVgvPjZiTR?=	NXLuT3hZOjJ\|M{[yOFY>
Trypanosoma brucei brucei	NFryTHlHfW6ldHnvckBCe3OjeR?=	MVSyNFAhdk1?	MWqxNkBp	NXPCNYRjTE2VTx?=	MWDE[YNz\WG\|ZTDpckBxcG:\|cHjveIllgWxiaX7vd4l1d2xicHjvd5Bp[XSnIHzleoVt	MUSyOFgxPTl2Nh?=
Trypanosoma brucei brucei	MmW1SpVv[3Srb36gRZN{[Xl?		MWexPEBp	NEfJVHJFVVOR	MU\Jcohq[mm2aX;uJI9nKHKnY3XweI9zNW2nZHnheIVlKGWwZH;jfZRwe2m\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHS{YX7z[oVzemmwIIXweIFs\Q>?	NIC0S4wzPDhyNUm0Oi=>
Trypanosoma brucei brucei	NWOxTWZtTnWwY4Tpc44hSXO\|YYm=	MYeyNFAhdk1?	NWruc4V1OTJiaB?=	NGfVTZVFVVOR	NV;MPYdETW[oZXP0JI9vKHOyaHnu[49ugWynaX6gcIV3\Wx?	M165WFI1QDB3OUS2
Trypanosoma brucei brucei	NUTXXGtTTnWwY4Tpc44hSXO\|YYm=	M4HrV\|IxOCCwTR?=	NWmxUWU4OTJiaB?=	MVzEUXNQ	M1HB[mVn\mWldDDvckBxcG:\|cHjheIllgWylaH;sbY5mKGyndnXs	NV;m[YptOjR6MEW5OFY>
UM-UC-3	NFTMb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\2VnRCUUN3ME2zNVUheE1?	M3fuVnNCVkeHUh?=
SBC-1	MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3zTWM2OD15NEKgdG0>	M2f2OXNCVkeHUh?=
MKN1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUKzc4VHUUN3ME2yMlghdk1?	MnvaV2FPT0WU
NCI-H720	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTNwNUegcm0>	M4rOb3NCVkeHUh?=
BFTC-909	NVnydZpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnpTWM2OD1\|LkexJI5O	M3PmPHNCVkeHUh?=
BPH-1	NEn6UJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzhe4RKSzVyPUSuO\|Yhdk1?	MonjV2FPT0WU
PC-3	MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTVwMEmgcm0>	NX[zV45kW0GQR1XS
AN3-CA	M4XkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\sSINKUUN3ME21MlU3KG6P	NF3kcGFUSU6JRWK=
HN	NGCwUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rGSWlEPTB;NT65OkBvVQ>?	NYXJUWVlW0GQR1XS
HCC2218	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzDc\|BsUUN3ME22MlYyKG6P	MYXTRW5ITVJ?
KP-4	NXfLXWNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfXTpdRUUN3ME23JI5O	M1PI[3NCVkeHUh?=
LU-139	Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13rZ2lEPTB;Nz63O{BvVQ>?	NXrQZ\|c6W0GQR1XS
ETK-1	MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\Zflh1UUN3ME23Mlg5KG6P	MoHtV2FPT0WU
Ramos-2G6-4C10	NITxVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRThwNEmgcm0>	NUP4NlN4W0GQR1XS
MHH-PREB-1	NUjycoUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXLTWM2OD17LkGyJI5O	NGDwbIJUSU6JRWK=
DU-4475	MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vIWGlEPTB;OT60OEBvVQ>?	MlTrV2FPT0WU
NCI-H1666	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLrcZRKSzVyPUmuO\|Ehdk1?	Mn7wV2FPT0WU
CAMA-1	M{DNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHlbndUUUN3ME25Mlghdk1?	M4n1WnNCVkeHUh?=
TYK-nu	MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3abpNvUUN3ME25Mlk1KG6P	NFjaPZRUSU6JRWK=
MFE-280	M{CySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\ydZhKSzVyPUmuPVkhdk1?	NHTqZmlUSU6JRWK=
A549	MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{C4O2lEPTB;MUCuNVQhdk1?	NGfKN21USU6JRWK=
769-P	NHq3RYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPVWHJKSzVyPUGwMlQ1KG6P	NUDSbWdqW0GQR1XS
L-363	MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHz1Z29KSzVyPUGwMlY6KG6P	M{HWTnNCVkeHUh?=
ES8	Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHTVToNKSzVyPUGwMlkhdk1?	M4DkPHNCVkeHUh?=
PA-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXyOFhJUUN3ME2xNU45OiCwTR?=	NITzNIVUSU6JRWK=
Mewo	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGH5V5lKSzVyPUGxMlk6KG6P	M1L0fXNCVkeHUh?=
HSC-3	M{HNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrNWWdTUUN3ME2xNk4zOSCwTR?=	MVnTRW5ITVJ?
H4	NFHlU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7v[\|RKSzVyPUGyMlY4KG6P	NYS0Z5U3W0GQR1XS
BB65-RCC	MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTF{LkeyJI5O	M17NV3NCVkeHUh?=
NCI-H1793	NVzO[IRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TIcWlEPTB;MUKuPFIhdk1?	M3:wcHNCVkeHUh?=
KARPAS-45	NWWwT3B7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXsWJBKSzVyPUGzMlUyKG6P	NX\4XYNkW0GQR1XS
GCT	M1T3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13Gd2lEPTB;MUOuOlghdk1?	NGLtdIlUSU6JRWK=
EoL-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PaVGlEPTB;MUOuPVMhdk1?	MYXTRW5ITVJ?
LB2241-RCC	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjYVWdKSzVyPUG0MlAyKG6P	NGr0b\|dUSU6JRWK=
ES5	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTF2Lke0JI5O	MXjTRW5ITVJ?
LOXIMVI	NU\IPIt2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTF2Lkm5JI5O	NXXNNWNyW0GQR1XS
COR-L105	MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXu5ZlRmUUN3ME2xOU4xPCCwTR?=	NV;2UYR5W0GQR1XS
P12-ICHIKAWA	NFzWbZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojxTWM2OD1zNT6xJI5O	NGW2dZVUSU6JRWK=
CHL-1	M2C3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTF3LkS1JI5O	MljRV2FPT0WU
VMRC-RCZ	NYX1dW46T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTF3Lk[zJI5O	MoXXV2FPT0WU
HH	NXmx[3FtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzUeFRKSzVyPUG1Mlchdk1?	MmThV2FPT0WU
NUGC-3	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTtTWM2OD1zNj6zOEBvVQ>?	Ml;TV2FPT0WU
EGI-1	NInldmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXuWIdWUUN3ME2xOk41OyCwTR?=	M4f2UHNCVkeHUh?=
OS-RC-2	MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnsTWM2OD1zNj60O{BvVQ>?	M1nLOHNCVkeHUh?=
MOLT-16	NVq5SXpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{L5TmlEPTB;MUeuNVUhdk1?	M1;JZ3NCVkeHUh?=
NCI-H209	NVjuRlIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTF5LkK5JI5O	MnW4V2FPT0WU
697	NF3WN\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTF5LkSzJI5O	MVHTRW5ITVJ?
D-56MG	MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnJNopXUUN3ME2xO{43QSCwTR?=	MnHiV2FPT0WU
VA-ES-BJ	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTF5LkizJI5O	MmL0V2FPT0WU
EW-16	MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\jTGhKSzVyPUG4MlA1KG6P	MnLqV2FPT0WU
HGC-27	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnWfnZKSzVyPUG4MlA3KG6P	NFW1eHJUSU6JRWK=
ES7	M4Dn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUGxN3JIUUN3ME2xPE4xQSCwTR?=	MVPTRW5ITVJ?
HuH-7	NFjzTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;2eWlEPTB;MUiuOEBvVQ>?	M2n1fHNCVkeHUh?=
BCPAP	M{HxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTF6Lk[1JI5O	Ml;MV2FPT0WU
SW1710	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFS1OmVKSzVyPUG4MlczKG6P	NF7QcIFUSU6JRWK=
IST-MEL1	NUX2WXJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXJTWM2OD1zOD63O{BvVQ>?	NYn1[HNpW0GQR1XS
SF295	M1\TSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzYVoJGUUN3ME2xPE46OyCwTR?=	MUPTRW5ITVJ?
RPMI-7951	M1riRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\5RYVKSzVyPUG5MlI5KG6P	NH3TW3pUSU6JRWK=
SF126	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTF7LkSxJI5O	MVPTRW5ITVJ?
GAMG	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTF7LkS4JI5O	NF;pXGZUSU6JRWK=
KNS-81-FD	M2L4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFm3emdKSzVyPUG5MlU1KG6P	NEHWRXRUSU6JRWK=
RT-112	NXnrSVdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrBR5l4UUN3ME2xPU43PiCwTR?=	MVvTRW5ITVJ?
DEL	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfj[XpKSzVyPUKwMlQ6KG6P	NYDmWIhGW0GQR1XS
CGTH-W-1	NX;zTZlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH32cGJKSzVyPUKwMlY{KG6P	MnrIV2FPT0WU
HOS	NYTlNm55T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTJzLkC2JI5O	MnvkV2FPT0WU
ES4	NVjRepI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTJzLkC4JI5O	Ml;VV2FPT0WU
RXF393	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrXcmpyUUN3ME2yNU41PSCwTR?=	Mmr2V2FPT0WU
NCI-H2030	MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PZSmlEPTB;MkGuOVIhdk1?	M2f4T3NCVkeHUh?=
YH-13	NX7sOll5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\Ib2FKSzVyPUKxMlg5KG6P	NV;2NXhoW0GQR1XS
HT-1080	NHfFVHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHL3SHVKSzVyPUKxMlk{KG6P	M1L2[nNCVkeHUh?=
NCI-SNU-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXMSnhKSzVyPUKxMlk2KG6P	NUXuUlFDW0GQR1XS
G-402	M33kN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTJ{LkG2JI5O	NIDtdI1USU6JRWK=
786-0	NWLqR2tVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWWwWFR5UUN3ME2yNk4zQSCwTR?=	M1[wWXNCVkeHUh?=
ME-180	NXW1UG1JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnjTWM2OD1{Mj60N{BvVQ>?	MnO2V2FPT0WU
NB69	M{LrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPFPWVKSzVyPUKyMlU{KG6P	MkjqV2FPT0WU
J-RT3-T3-5	M4HZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1ixbGlEPTB;MkKuPVYhdk1?	MlW2V2FPT0WU
TGBC1TKB	MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13Hc2lEPTB;MkOuNFUhdk1?	NEO5copUSU6JRWK=
SW780	NHLjTnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PpUWlEPTB;MkOuNVMhdk1?	NYK1dnZHW0GQR1XS
MG-63	M4PsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TVNmlEPTB;MkOuOFUhdk1?	NEK2U2pUSU6JRWK=
BV-173	MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVX3TpZmUUN3ME2yN{45PyCwTR?=	NF24b2NUSU6JRWK=
CAL-51	NV;nW2dHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2W5T2lEPTB;MkOuPFkhdk1?	MVvTRW5ITVJ?
A375	NGrybopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\1TWM2OD1{Mz65N{BvVQ>?	MWnTRW5ITVJ?
MEL-HO	MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTLUZJzUUN3ME2yOE4xPCCwTR?=	NIHSPG9USU6JRWK=
EFO-27	M{Cy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;YNYtnUUN3ME2yOE4{OyCwTR?=	NInHOHlUSU6JRWK=
Hs-578-T	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTPfJlKSzVyPUK0MlU5KG6P	MlvOV2FPT0WU
NBsusSR	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTm[JlKSzVyPUK0MlYhdk1?	MorBV2FPT0WU
CTB-1	M164c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfKfYpKSzVyPUK0MlY4KG6P	M1HFXXNCVkeHUh?=
FTC-133	M4LVZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTUTWM2OD1{NT6xJI5O	M{e4S3NCVkeHUh?=
MOLT-4	NEDMNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEKyNnhKSzVyPUK1MlEzKG6P	M{HrOHNCVkeHUh?=
HO-1-N-1	NV62cFVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjMTWM2OD1{NT6xOUBvVQ>?	NGrMNHFUSU6JRWK=
ES3	NVHyO\|FqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTJ3LkKyJI5O	NUfwPXpvW0GQR1XS
TI-73	MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXpZZpKSzVyPUK1MlI5KG6P	M3fj[XNCVkeHUh?=
MPP-89	NEjiOoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvrTFloUUN3ME2yOU4{OiCwTR?=	M3\wbnNCVkeHUh?=
KYSE-150	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;kNFVKSzVyPUK1Mlg6KG6P	NVjWN3puW0GQR1XS
LXF-289	NGDOemxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjZVYNKSzVyPUK2MlA1KG6P	NFG0R\|dUSU6JRWK=
SK-LU-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M321cWlEPTB;Mk[uNVchdk1?	M3iwT3NCVkeHUh?=
HOP-92	M{TZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHITWM2OD1{Nj60PEBvVQ>?	NVzS[2RrW0GQR1XS
HuO9	NILSNI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTJ4Lke2JI5O	MlLrV2FPT0WU
SW962	NG\Fe4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELNNpZKSzVyPUK2Mlc3KG6P	NYXrSGFoW0GQR1XS
RS4-11	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrhbW81UUN3ME2yOk46OSCwTR?=	NF\tR4NUSU6JRWK=
NCI-H292	Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jveWlEPTB;Mkegcm0>	MVrTRW5ITVJ?
DB	MlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\1TGlEPTB;MkeuN\|Yhdk1?	NFjOe5dUSU6JRWK=
SW1088	NGDibY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHkRYhKSzVyPUK4MlI6KG6P	NWCxSnJTW0GQR1XS
A204	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTJ6LkS3JI5O	M4rzSHNCVkeHUh?=
A3-KAW	NIXQPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvvblFlUUN3ME2yPE43PCCwTR?=	NXX5eo1jW0GQR1XS
MV-4-11	Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTJ6Lkegcm0>	M1nlfXNCVkeHUh?=
ES1	NI\PbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfuUWZTUUN3ME2yPE45PCCwTR?=	M1KyWHNCVkeHUh?=
ONS-76	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\FZmlEPTB;MkmuNFUhdk1?	MX\TRW5ITVJ?
D-263MG	NXTKV20xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPseJBKSzVyPUK5MlM2KG6P	M4XmfnNCVkeHUh?=
U-2-OS	NIS5XHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\uTWM2OD1{OT61JI5O	NF[2R4ZUSU6JRWK=
T98G	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\H[JRCUUN3ME2yPU45QCCwTR?=	NGPaeJhUSU6JRWK=
GI-ME-N	NI[3b4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTJ7LkmxJI5O	MWHTRW5ITVJ?
BHT-101	NIfCTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTNyLkC1JI5O	M1HYSnNCVkeHUh?=
NOS-1	NYXxcFE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTNyLkGyJI5O	M4rw[HNCVkeHUh?=
AsPC-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDCTWM2OD1\|MD6yJI5O	NXL3cpdnW0GQR1XS
QIMR-WIL	Mkn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\ibY01UUN3ME2zNE43KG6P	MXLTRW5ITVJ?
JVM-3	NFP4eFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vlZmlEPTB;M{CuPFMhdk1?	M2SzT3NCVkeHUh?=
KU-19-19	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnn6TWM2OD1\|MT6xN{BvVQ>?	M2Wz[3NCVkeHUh?=
OVCAR-8	NUXj[49RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzQTWM2OD1\|MT6yOkBvVQ>?	NX3CTW9RW0GQR1XS
BEN	NX31NHd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknwTWM2OD1\|MT62N{BvVQ>?	NXHpRohCW0GQR1XS
BE-13	NXm4doduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfMboJKSzVyPUOxMlgzKG6P	MVTTRW5ITVJ?
EW-18	NXGy[\|RQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfPSo1xUUN3ME2zNU45PiCwTR?=	MX;TRW5ITVJ?
ECC10	NUS0b29ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTNzLkm1JI5O	MlHXV2FPT0WU
CTV-1	NXuySld2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfVR2Y6UUN3ME2zNk45OiCwTR?=	MWTTRW5ITVJ?
COLO-800	MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\QTWM2OD1\|Mj65NkBvVQ>?	NHHDT5JUSU6JRWK=
A2058	NEfaZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfF[XpqUUN3ME2zN{4zPSCwTR?=	MnTzV2FPT0WU
VM-CUB-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjjV25pUUN3ME2zN{41OyCwTR?=	NHKzb5NUSU6JRWK=
Ca9-22	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPRfZRKSzVyPUOzMlU2KG6P	MnKwV2FPT0WU
COLO-684	NITmV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTN\|LkW4JI5O	MYXTRW5ITVJ?
RPMI-8226	Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPOTWM2OD1\|Mz64NkBvVQ>?	NX3NRot5W0GQR1XS
SK-NEP-1	NYXDPYUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjwZnNKSzVyPUO0MlE2KG6P	MX3TRW5ITVJ?
Becker	NIjV[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFqyT2ZKSzVyPUO0MlIyKG6P	MnTGV2FPT0WU
NCI-H28	MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PYeWlEPTB;M{SuOFQhdk1?	NF23cHFUSU6JRWK=
CAL-120	NF\MV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\2XWlEPTB;M{SuO\|Ihdk1?	M3[5dXNCVkeHUh?=
MDA-MB-157	MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jxOGlEPTB;M{WuOFEhdk1?	MV\TRW5ITVJ?
OVCAR-5	NVzGeZc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFKzcnNKSzVyPUO1MlQ4KG6P	MYTTRW5ITVJ?
LAMA-84	MlrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XQbmlEPTB;M{WuPFchdk1?	NHTSdVFUSU6JRWK=
CAKI-1	NWm5dFB3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTN4LkSzJI5O	NX3yTXFiW0GQR1XS
Daoy	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfMNZR2UUN3ME2zOk44KG6P	MXXTRW5ITVJ?
CAL-62	NEPUeWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nme2lEPTB;M{[uPFYhdk1?	M3rnNnNCVkeHUh?=
8-MG-BA	NITUVHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrtXGRzUUN3ME2zO{4zPSCwTR?=	M{jmT3NCVkeHUh?=
8505C	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnP6TWM2OD1\|Nz61NUBvVQ>?	MYTTRW5ITVJ?
LNCaP-Clone-FGC	NYLBcHdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTN5LkW5JI5O	NIm0S\|ZUSU6JRWK=
CAL-39	NEHZS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTBTWM2OD1\|Nz65JI5O	MYXTRW5ITVJ?
MN-60	NW[5bYFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTN5Lkm2JI5O	MXLTRW5ITVJ?
RKO	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTN6LkOzJI5O	MVfTRW5ITVJ?
U251	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\Sc3lnUUN3ME2zPE41OyCwTR?=	NF3RN5FUSU6JRWK=
SJSA-1	NXzlbZJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jOTGlEPTB;M{iuOVQhdk1?	MX;TRW5ITVJ?
CAL-12T	NFq2eIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTN6Lk[gcm0>	Mk\ZV2FPT0WU
HCC1419	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPkW4Z1UUN3ME2zPE44OSCwTR?=	NV7WS5I1W0GQR1XS
CO-314	M4rwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDTdWtKSzVyPUO4Mlc1KG6P	M1W2PXNCVkeHUh?=
LB1047-RCC	NYHze5VwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTN6LkixJI5O	M4fsSHNCVkeHUh?=
A101D	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljyTWM2OD1\|OD65O{BvVQ>?	NYfWbldnW0GQR1XS
MDA-MB-175-VII	MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTN7LkWxJI5O	MlX1V2FPT0WU
MZ2-MEL	MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjITWM2OD1\|OT62OkBvVQ>?	MmCyV2FPT0WU
NB5	NWPIcYFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rFcmlEPTB;NECuOlQhdk1?	MYrTRW5ITVJ?
G-401	MonCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vTOmlEPTB;NECuPFIhdk1?	Ml3JV2FPT0WU
HT	NI\MfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2[5cmlEPTB;NEGuNFIhdk1?	NFPtSmFUSU6JRWK=
8305C	MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnq3TWM2OD12MT64O{BvVQ>?	M33qb3NCVkeHUh?=
BHY	MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGn0[GtKSzVyPUSyMlczKG6P	NVPlWY5OW0GQR1XS
NTERA-S-cl-D1	Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH:0UIlKSzVyPUSzJI5O	NFT5fFVUSU6JRWK=
T-24	Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlv4TWM2OD12Mz64N{BvVQ>?	Mn\GV2FPT0WU
EPLC-272H	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTR2LkO5JI5O	M1HaZ3NCVkeHUh?=
PSN1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorUTWM2OD12ND60JI5O	MnPKV2FPT0WU
NCI-H2452	NYrmd452T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDw[IVKSzVyPUS0MlU5KG6P	NXru[YVnW0GQR1XS
KS-1	MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnQPGRKSzVyPUS0MlY3KG6P	MnjIV2FPT0WU
HD-MY-Z	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmH3TWM2OD12ND65NkBvVQ>?	MVjTRW5ITVJ?
KNS-62	MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEn3eVhKSzVyPUS1MlM5KG6P	MVXTRW5ITVJ?
NOMO-1	MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTR3Lki3JI5O	NFnwN21USU6JRWK=
SK-HEP-1	NUHKcYRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTR4LkC0JI5O	MX7TRW5ITVJ?
IGR-1	NFz6XYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HmOGlEPTB;NE[uNVMhdk1?	NFPRV\|RUSU6JRWK=
KYSE-180	NHvOdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzwTWM2OD12Nj6xO{BvVQ>?	Mn31V2FPT0WU
EW-22	NHP2fVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3yxOmlEPTB;NE[uNkBvVQ>?	MWPTRW5ITVJ?
NCI-H1355	MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHrdGN2UUN3ME20Ok4{PCCwTR?=	M2nBO3NCVkeHUh?=
DOHH-2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTR4LkO3JI5O	MVHTRW5ITVJ?
A4-Fuk	M1:3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTR4LkWyJI5O	M3yyfXNCVkeHUh?=
PC-14	NYXnTppCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHhdoRKSzVyPUS2MlU4KG6P	M1XBbHNCVkeHUh?=
TE-5	NGr1UmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfLTWM2OD12Nj64OEBvVQ>?	NV3Hb\|lUW0GQR1XS
LB996-RCC	MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\WfGlEPTB;NEeuNVkhdk1?	M37lbXNCVkeHUh?=
NCI-H1623	M3;Ddmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTR5Lke2JI5O	NWnhVnJbW0GQR1XS
NCI-H1155	NIewTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfnWGt6UUN3ME20PE4{OiCwTR?=	M{mxU3NCVkeHUh?=
LoVo	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jtN2lEPTB;NEiuOEBvVQ>?	MWHTRW5ITVJ?
MCF7	MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDtSFM3UUN3ME20PE42QCCwTR?=	MnLUV2FPT0WU
AGS	NY[5N\|lFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWT3Z3BnUUN3ME20PE44PyCwTR?=	M{PiSnNCVkeHUh?=
PFSK-1	NES5RlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLIOJlKSzVyPUS5MlA3KG6P	M2LsUnNCVkeHUh?=
22RV1	MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHDNGJpUUN3ME20PU4xQSCwTR?=	MlLoV2FPT0WU
COR-L23	NVX0T4VjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojRTWM2OD12OT6xOkBvVQ>?	Mlj1V2FPT0WU
D-283MED	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nxXGlEPTB;NEmuOlEhdk1?	MXnTRW5ITVJ?
SW982	NWfrR4dmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XSfWlEPTB;NEmuPVEhdk1?	MmTPV2FPT0WU
SW620	NYDQNZZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Dmd2lEPTB;NUCuN\|Yhdk1?	NETIcHRUSU6JRWK=
KYSE-140	NXLrUVhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTVyLkW1JI5O	NHHsOlJUSU6JRWK=
GCIY	NGL4TJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFToXlFKSzVyPUWwMlY4KG6P	M1PLenNCVkeHUh?=
MHH-ESS-1	MmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofxTWM2OD13MT65OUBvVQ>?	NHy2VnBUSU6JRWK=
D-423MG	NYPCTII5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDJTWM2OD13Mj6wPEBvVQ>?	NVmxPHJLW0GQR1XS
SF539	NXH4T\|QyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfJWnM4UUN3ME21Nk4{PSCwTR?=	MnHjV2FPT0WU
RPMI-2650	NIXsO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTV{Lk[5JI5O	NH3pU5JUSU6JRWK=
GR-ST	M1HZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTV{Lki3JI5O	NGfyN21USU6JRWK=
YKG-1	MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTkSotKSzVyPUWzJI5O	NHG0ZYxUSU6JRWK=
SK-MES-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUn3codbUUN3ME21N{4zPiCwTR?=	MknYV2FPT0WU
HLE	M4fFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULCXGxCUUN3ME21N{41PyCwTR?=	MlyzV2FPT0WU
RVH-421	NH\NWWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLUcoxKSzVyPUWzMlY4KG6P	NUHVOHNIW0GQR1XS
C32	Mlm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPTUXVKSzVyPUWzMlg{KG6P	NVHCVI1rW0GQR1XS
GB-1	NFiyfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmriTWM2OD13ND6yJI5O	MVHTRW5ITVJ?
SNB75	NVvCNWd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\2UXI1UUN3ME21OE4zPiCwTR?=	M1O4THNCVkeHUh?=
EM-2	NGrxco5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfFXnRSUUN3ME21OE41KG6P	M4jjcXNCVkeHUh?=
RH-1	M1rFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DSVWlEPTB;NUSuO{BvVQ>?	NIOwblZUSU6JRWK=
NKM-1	NIPxNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrMTWM2OD13ND64NUBvVQ>?	NGD1fphUSU6JRWK=
NCI-H2405	NIe2VVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33id2lEPTB;NUSuPFghdk1?	MnHEV2FPT0WU
KYSE-450	NUTE[oxFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGK5fo9KSzVyPUW1MlE3KG6P	MWrTRW5ITVJ?
A704	NF3C[2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTV3LkW5JI5O	M1jZeXNCVkeHUh?=
HAL-01	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmC2TWM2OD13NT64N{BvVQ>?	NHvofYtUSU6JRWK=
TE-11	M16xcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\w[4pkUUN3ME21OU46QSCwTR?=	M1PLS3NCVkeHUh?=
DOK	NF\oUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn36TWM2OD13Nj6wNkBvVQ>?	M{Tn[XNCVkeHUh?=
KY821	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fnTmlEPTB;NU[uNkBvVQ>?	NY\x[XlqW0GQR1XS
KGN	NETldpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTV4LkOyJI5O	NVnQ[2wyW0GQR1XS
MC116	MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnDS5dOUUN3ME21O{45KG6P	MX;TRW5ITVJ?
PANC-08-13	MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\WSWlEPTB;NUiuNFEhdk1?	M2rleHNCVkeHUh?=
KE-37	M1Xu[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFizd\|VKSzVyPUW4Mlc4KG6P	NHH6OlZUSU6JRWK=
KYSE-410	NXXj[45wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTV7LkS3JI5O	NGTINmFUSU6JRWK=
RO82-W-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTV7Lkmgcm0>	MXrTRW5ITVJ?
M14	MoDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLvTWM2OD14MD6wOEBvVQ>?	NInwd2ZUSU6JRWK=
GI-1	MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUOwSXB1UUN3ME22NE4{KG6P	MWDTRW5ITVJ?
ML-2	NXyyeJQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTZyLk[yJI5O	MmjYV2FPT0WU
BFTC-905	NH:5XYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHKWFJNUUN3ME22NE43PSCwTR?=	NVjJeWZlW0GQR1XS
DMS-273	M2P5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3raRmlEPTB;NkCuPFchdk1?	NX;YOFE2W0GQR1XS
MDA-MB-361	MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\ZbWlEPTB;NkGgcm0>	M1nFV3NCVkeHUh?=
MSTO-211H	M2\HNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknGTWM2OD14Mz61NUBvVQ>?	MVLTRW5ITVJ?
MEG-01	M3LhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTZ\|LkWyJI5O	MkKxV2FPT0WU
M059J	NGfGTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrId4xKSzVyPU[zMlU5KG6P	MkCwV2FPT0WU
LN-405	M{jCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4[4XGlEPTB;NkOuPFUhdk1?	M1;CV3NCVkeHUh?=
NCI-H1581	MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm[yTWM2OD14ND6wN{BvVQ>?	MXnTRW5ITVJ?
TCCSUP	NVjyXHozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTZ2LkWzJI5O	NHfid2tUSU6JRWK=
SW872	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlz3TWM2OD14ND61O{BvVQ>?	MVzTRW5ITVJ?
KYSE-510	M3ryZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTZ3Lke1JI5O	NIrXS2hUSU6JRWK=
NCI-H1792	M2PW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;yWmlEPTB;Nk[uNVUhdk1?	M3;TR3NCVkeHUh?=
SW13	NGLKT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\XU2lEPTB;Nk[uOUBvVQ>?	MkTxV2FPT0WU
TE-8	MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\GbIRKSzVyPU[2MlUzKG6P	M4PlV3NCVkeHUh?=
SCH	M2HlNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\hTWM2OD14Nz6xJI5O	NHPJU\|BUSU6JRWK=
NEC8	M4fLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlz6TWM2OD14Nz6yOEBvVQ>?	MYPTRW5ITVJ?
HuO-3N1	NXnZS2V1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7z[mlZUUN3ME22O{4{OSCwTR?=	MWjTRW5ITVJ?
EFM-19	NHT2coFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\G[4tJUUN3ME22O{42KG6P	NIqzflFUSU6JRWK=
HEC-1	NGrsW5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorlTWM2OD14Nz61NkBvVQ>?	MkTyV2FPT0WU
T47D	NXG1cXBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofqTWM2OD14Nz64O{BvVQ>?	NYjkXHhoW0GQR1XS
SNU-423	NYLLbVROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzyTlBKSzVyPU[3Mlk5KG6P	NX33d\|E5W0GQR1XS
WM-115	NITYU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7TVVZKSzVyPU[4MlE1KG6P	Ml6xV2FPT0WU
CaR-1	MnnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITXR29KSzVyPU[4MlI2KG6P	MnvBV2FPT0WU
KU812	NVTKcmJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHtTWM2OD14OD62PUBvVQ>?	M1PifnNCVkeHUh?=
AM-38	NF;3ZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkC4TWM2OD14OT6zNUBvVQ>?	NILBe4dUSU6JRWK=
KOSC-2	NWG0OHZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3uTWM2OD14OT65O{BvVQ>?	NIP3[IxUSU6JRWK=
MC-IXC	MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLac5hFUUN3ME23NE4xQCCwTR?=	MnK2V2FPT0WU
SCC-4	NVOxPIRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLoXW9{UUN3ME23NU4{QCCwTR?=	Mn22V2FPT0WU
Calu-3	Moj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrlTI1rUUN3ME23NU46QCCwTR?=	MU\TRW5ITVJ?
RPMI-8866	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DXNWlEPTB;N{KuPFIhdk1?	Ml7EV2FPT0WU
OVCAR-4	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDoTWM2OD15Mz6zOkBvVQ>?	MYfTRW5ITVJ?
OAW-42	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4f5TmlEPTB;N{OuN\|khdk1?	MWTTRW5ITVJ?
ATN-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3yTWM2OD15Mz64O{BvVQ>?	M2rlSHNCVkeHUh?=
CHP-212	MoPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\FW29PUUN3ME23OE46PSCwTR?=	NGe5V\|VUSU6JRWK=
C2BBe1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPNZVlNUUN3ME23OU4xOyCwTR?=	M1PYbnNCVkeHUh?=
A498	M17RNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfzTWM2OD15NT6xOUBvVQ>?	NFHZZlVUSU6JRWK=
SH-4	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDlTWM2OD15NT6yNUBvVQ>?	NIn6Ro5USU6JRWK=
SNU-449	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXO4blI6UUN3ME23OU44QSCwTR?=	Mn;IV2FPT0WU
RD	NIXNRY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFv5d2VKSzVyPUe1Mlg3KG6P	NGfwTGlUSU6JRWK=
PANC-03-27	MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTd4LkK1JI5O	MkX4V2FPT0WU
S-117	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTPTWM2OD15Nj6yO{BvVQ>?	M{f0cXNCVkeHUh?=
SK-MEL-2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXpTWM2OD15Nj63OUBvVQ>?	NXHNUWlmW0GQR1XS
LK-2	NVjCdWNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHrNppzUUN3ME23O{4xPSCwTR?=	M1HoU3NCVkeHUh?=
CP50-MEL-B	M{XHbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\ZbmlEPTB;N{euOEBvVQ>?	MUnTRW5ITVJ?
647-V	Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjvTWM2OD15OD6wO{BvVQ>?	MYDTRW5ITVJ?
LU-134-A	Ml:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NED1WYpKSzVyPUe5MlA{KG6P	NV\oWI1oW0GQR1XS
5637	Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPTTFFKSzVyPUe5MlI{KG6P	MY\TRW5ITVJ?
NCI-H1437	MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\LTWM2OD16MD61JI5O	NIriWpFUSU6JRWK=
NCI-H460	NWfqd49GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX;WfFJnUUN3ME24NU4zOyCwTR?=	NGHldFNUSU6JRWK=
BxPC-3	M4ro[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnuxTWM2OD16MT60OkBvVQ>?	M1X6c3NCVkeHUh?=
CAN	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jZbWlEPTB;OEGuPFQhdk1?	MUjTRW5ITVJ?
KINGS-1	NF3yNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NET5dIZKSzVyPUiyMlMzKG6P	Mn7hV2FPT0WU
OCUB-M	NX7jd4lJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fYbmlEPTB;OEKuOFEhdk1?	MmHiV2FPT0WU
KALS-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1e4fGlEPTB;OEKuOVQhdk1?	NH7FUZhUSU6JRWK=
OCI-AML2	MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTFeJdKSzVyPUiyMlYyKG6P	MknhV2FPT0WU
A253	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTh{Lk[1JI5O	MVrTRW5ITVJ?
LCLC-97TM1	NITwOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTzT41FUUN3ME24Nk45PiCwTR?=	MmnZV2FPT0WU
NCI-H520	M3HC[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37qNGlEPTB;OEOuNFYhdk1?	NXHKdng6W0GQR1XS
P30-OHK	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTh\|LkWgcm0>	NUexN5hZW0GQR1XS
SBC-5	MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfiXWxKSzVyPUizMlUzKG6P	MWrTRW5ITVJ?
HCE-T	NGfG[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTh\|Lke0JI5O	MlWzV2FPT0WU
JEG-3	NFe2NWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfpfGZKSzVyPUi0MlEhdk1?	M1\TOHNCVkeHUh?=
KG-1	MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTh2LkK0JI5O	NUnpS4pSW0GQR1XS
MIA-PaCa-2	NFvabVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTh2LkW0JI5O	M{LzS3NCVkeHUh?=
CAL-33	NUG0VI9{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LNUGlEPTB;OEWuNFghdk1?	NIjDNIZUSU6JRWK=
639-V	NXPKUXVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7Kb2Q2UUN3ME24OU41OiCwTR?=	MUjTRW5ITVJ?
NCI-H1048	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDXeFV1UUN3ME24Ok4{OSCwTR?=	M1zpVXNCVkeHUh?=
NCI-H1573	MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2Swd2lEPTB;OEeuOFghdk1?	MVvTRW5ITVJ?
NCI-H2228	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\NTWM2OD16OD6yOkBvVQ>?	MYnTRW5ITVJ?
NB14	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7JTlBYUUN3ME24PE4{KG6P	MoTyV2FPT0WU
SCC-25	Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfLXWpKSzVyPUi5MlgzKG6P	NIj3UHpUSU6JRWK=
A431	NUDX[Y1bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1fqOmlEPTB;OEmuPVchdk1?	MkH2V2FPT0WU
SN12C	MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTlyLk[yJI5O	M3nMeXNCVkeHUh?=
HuCCT1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTlyLke2JI5O	M3\1d3NCVkeHUh?=
LS-123	MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTl{LkG4JI5O	M{LQSXNCVkeHUh?=
CAL-85-1	MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXpTWM2OD17Mj60PEBvVQ>?	M2qx[XNCVkeHUh?=
ES6	MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTl{LkizJI5O	MlzCV2FPT0WU
NCI-H650	NETtRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXVUmNjUUN3ME25OE4xQSCwTR?=	NYX6cnFsW0GQR1XS
NCI-H446	M1frNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTl3LkGyJI5O	M{HYRXNCVkeHUh?=
EW-13	M4[zU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTl3Lke1JI5O	NHW0fHVUSU6JRWK=
HSC-2	M{PaTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWixdIYxUUN3ME25OU45QSCwTR?=	MnrMV2FPT0WU
U031	M4fNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XqSWlEPTB;OU[uO\|Mhdk1?	NWmzeXZLW0GQR1XS
EW-11	M1zJSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXucXdKSzVyPUm2Mlg5KG6P	MUHTRW5ITVJ?
GAK	NEXCeYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjNPI9KSzVyPUm4Mlk{KG6P	NHX5PYlUSU6JRWK=
SK-OV-3	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTs[nFwUUN3ME2xNFAvODdibl2=	NUi0dVhpW0GQR1XS
OMC-1	NXPGRmxkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPseGxtUUN3ME2xNFAvOThibl2=	NIH0b5ZUSU6JRWK=
TK10	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTFyMD6yNUBvVQ>?	MlTFV2FPT0WU
EKVX	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTFyMD62JI5O	M4jETHNCVkeHUh?=
Detroit562	M1HsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PibWlEPTB;MUCyMlE4KG6P	Ml3WV2FPT0WU
SF268	Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fxTGlEPTB;MUCyMlM1KG6P	MnPrV2FPT0WU
SNU-387	NXH6O2l6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TjcmlEPTB;MUC0MlE4KG6P	NUDuWoVEW0GQR1XS
MDA-MB-231	M{\seGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXCS4xKSzVyPUGwOU4xPiCwTR?=	M1m1SHNCVkeHUh?=
NCI-H1563	NUnvdoJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rXRmlEPTB;MUC1MlE5KG6P	MUfTRW5ITVJ?
D-502MG	M1nUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTFyNT63JI5O	MX;TRW5ITVJ?
A2780	MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXqTWM2OD1zME[uOFchdk1?	NH6zNYxUSU6JRWK=
IA-LM	NUnuNIE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTFyNz61NUBvVQ>?	M1:1eXNCVkeHUh?=
D-392MG	M2jhSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjycFRKSzVyPUGwO{42PCCwTR?=	MVzTRW5ITVJ?
MS-1	MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTFyNz63NUBvVQ>?	M4rJOHNCVkeHUh?=
SW1990	NUTFXGU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\STWM2OD1zMEiuOVQhdk1?	NUGzNohvW0GQR1XS
HEL	M17tRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknmTWM2OD1zMEmuNlkhdk1?	NEfGeWZUSU6JRWK=
SW1573	M1;vOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUO2dnN[UUN3ME2xNFkvOzFibl2=	M{O1S3NCVkeHUh?=
SW1783	M4DPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTFzMD6yNkBvVQ>?	Mo\kV2FPT0WU
COLO-680N	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTFzMD63OkBvVQ>?	M16yNHNCVkeHUh?=
NCI-N87	NGPOR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTFzMT6wOEBvVQ>?	NVjFXXY2W0GQR1XS
SK-MEL-28	NX\jZXpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NED6S\|hKSzVyPUGxNU42PSCwTR?=	NF7SdWVUSU6JRWK=
BT-20	NEn0[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknPTWM2OD1zMUKuNFEhdk1?	MorEV2FPT0WU
NCI-H1648	Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknqTWM2OD1zMUOgcm0>	NX;BW3pQW0GQR1XS
no-11	MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTFzMz6yPEBvVQ>?	NXn4XpcyW0GQR1XS
MOLT-13	NIjzT3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTFzMz60OEBvVQ>?	MofMV2FPT0WU
NCI-H2170	M{TuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF72fmVKSzVyPUGxOE42OSCwTR?=	MmnsV2FPT0WU
HTC-C3	MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTFzNj64OUBvVQ>?	NF7rTYxUSU6JRWK=
LU-99A	NYK3THZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVqyUHNlUUN3ME2xNVcvOjFibl2=	NUi3d5pOW0GQR1XS
HCC2998	NX7pdFU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmC3TWM2OD1zMUeuPVIhdk1?	M3H5RXNCVkeHUh?=
NB13	NUTFTXlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2Tx[GlEPTB;MUG3Mlk6KG6P	NULBR5g2W0GQR1XS
GT3TKB	NY\YdFU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3PIUGlEPTB;MUG4MlA5KG6P	M{HKOXNCVkeHUh?=
BT-549	MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTFzOD65OUBvVQ>?	NILCOYlUSU6JRWK=
NCI-H747	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPBb\|dKSzVyPUGxPU4{PCCwTR?=	MWjTRW5ITVJ?
EW-1	M3;H[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2LScmlEPTB;MUKwMlIhdk1?	Moq0V2FPT0WU
LB831-BLC	NI\ZRolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTF{MD62N{BvVQ>?	M{TWVXNCVkeHUh?=
NMC-G1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml:1TWM2OD1zMkGuNVEhdk1?	M4TTSHNCVkeHUh?=
COLO-679	NEDtNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvQTWM2OD1zMkKuNVUhdk1?	MV\TRW5ITVJ?
HL-60	MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnCWlZyUUN3ME2xNlMvOSCwTR?=	MWjTRW5ITVJ?
MKN7	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFqxZoFKSzVyPUGyN{45OyCwTR?=	NHfafYdUSU6JRWK=
RERF-LC-MS	M3niVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPwcHJKSzVyPUGyOE4{OSCwTR?=	MnHBV2FPT0WU
DMS-114	NU\WT\|RZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoT6TWM2OD1zMkWuNFkhdk1?	NILkS2tUSU6JRWK=
HuP-T4	NYfNXod2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vHWWlEPTB;MUK2Mlk4KG6P	MorPV2FPT0WU
HCC2157	NHTOS5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTF{Nz61JI5O	MWfTRW5ITVJ?
SKG-IIIa	M1jaPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEi2S\|dKSzVyPUGyPE45KG6P	M3XzT3NCVkeHUh?=
HCT-116	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTF\|MD62OEBvVQ>?	M1rkS3NCVkeHUh?=
BB30-HNC	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljDTWM2OD1zM{CuO\|ghdk1?	MXrTRW5ITVJ?
KYSE-270	NUXOeI1MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4X2TGlEPTB;MUOwMlg5KG6P	NUHZOYtIW0GQR1XS
MFM-223	M3;TcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHri[VBKSzVyPUGzNU42OSCwTR?=	Ml3aV2FPT0WU
NH-12	M2ixbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnmZopoUUN3ME2xN\|IvQTlibl2=	MUfTRW5ITVJ?
U-118-MG	M3\Zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2H4[mlEPTB;MUOzMlYzKG6P	NYm3e5pnW0GQR1XS
ESS-1	NGXnT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrtdYxKSzVyPUGzOU4yQCCwTR?=	NVTaW4dxW0GQR1XS
D-247MG	NXTLWmd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTlSZY{UUN3ME2xN\|UvOjFibl2=	MWLTRW5ITVJ?
IGROV-1	MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnEOGNKSzVyPUGzOU44PiCwTR?=	M2\lOHNCVkeHUh?=
C-33-A	M3OxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjRTWM2OD1zM{WuPVchdk1?	NVXq[HlyW0GQR1XS
NCI-H1693	M4fOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NED1bnVKSzVyPUGzOk4yOiCwTR?=	Mn[5V2FPT0WU
MLMA	NYTMXWZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn[4TWM2OD1zM{[uOVghdk1?	NUD0U4xyW0GQR1XS
SK-N-AS	NIjuTIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnG2TWM2OD1zM{euNVchdk1?	MYHTRW5ITVJ?
NCI-H1755	MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETaUYVKSzVyPUGzPE45PSCwTR?=	MWXTRW5ITVJ?
CHP-134	M1S5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3e4TmlEPTB;MUO5MlU2KG6P	NIe3SndUSU6JRWK=
LS-513	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\uTWM2OD1zNECuPVEheE1?	M1;sb3NCVkeHUh?=
TE-12	NEP3VnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{e0Z2lEPTB;MUSwMlk{KG6P	MmTJV2FPT0WU
KNS-42	MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPFd2o{UUN3ME2xOFQvOyCwTR?=	M2f0UnNCVkeHUh?=
SJRH30	M1z1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LoPWlEPTB;MUS0MlQ1KG6P	M3jXfnNCVkeHUh?=
NCI-H1092	NUXkcJRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnP2TWM2OD1zNESuOVIhdk1?	M4Wwb3NCVkeHUh?=
H-EMC-SS	NF7RO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1q0UmlEPTB;MUS2MlgyKG6P	NVqxZlFyW0GQR1XS
SK-MEL-3	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MomyTWM2OD1zNEeuOVUhdk1?	MULTRW5ITVJ?
SK-N-FI	NYnFPGxST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnO5TWM2OD1zNEeuOVkhdk1?	NWezO5hsW0GQR1XS
NCI-H2126	M3;ZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NID3ZWNKSzVyPUG0PE4yPSCwTR?=	M4jNVnNCVkeHUh?=
NCI-H1299	M3\aOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTF3MD6yNkBvVQ>?	NEf1fmtUSU6JRWK=
CFPAC-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfsTWM2OD1zNUCuOlYhdk1?	MVLTRW5ITVJ?
NCI-H661	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzV[ZRKSzVyPUG1NU4zPiCwTR?=	NVfkfXo5W0GQR1XS
KYSE-70	MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\MUHdKSzVyPUG1NU44QSCwTR?=	M17xXnNCVkeHUh?=
SW900	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXG4OGN1UUN3ME2xOVQvPjVibl2=	NGfNfZJUSU6JRWK=
Ca-Ski	NXHLWYhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTF3Nj6zPUBvVQ>?	MXXTRW5ITVJ?
HPAF-II	M2fvXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonsTWM2OD1zNU[uOFchdk1?	NHHTNFdUSU6JRWK=
LB2518-MEL	NF3wSWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTF3Nz6xJI5O	NFy4eHlUSU6JRWK=
LC-2-ad	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInZOHFKSzVyPUG1PE43OiCwTR?=	NXXmR5ZbW0GQR1XS
HCC1806	NIHLXpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfQ[lh1UUN3ME2xOlcvQDhibl2=	NYWzRYt2W0GQR1XS
UACC-62	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjKT4NKSzVyPUG2PE4xQSCwTR?=	MlnrV2FPT0WU
KM-H2	M4PuUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PuNWlEPTB;MUewMlU5KG6P	M2fMRnNCVkeHUh?=
NCI-H2347	NIm2SHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUCz[oNmUUN3ME2xO\|IvPzJibl2=	MYPTRW5ITVJ?
SCC-15	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHKzSmZKSzVyPUG3N{43PiCwTR?=	NIXqfIhUSU6JRWK=
BB49-HNC	NXrHO4FzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzrTWM2OD1zN{OuPFEhdk1?	NU[4TYR1W0GQR1XS
GMS-10	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHe1eYRKSzVyPUG3N{46PCCwTR?=	NVv1fYdpW0GQR1XS
NCI-H2052	NF7xcZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\H[HFKSzVyPUG3OE46KG6P	NXLORpZWW0GQR1XS
SW626	M{DDdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1noRmlEPTB;MUe2MlA3KG6P	MofSV2FPT0WU
MDA-MB-415	NWf4OVdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHexeoRKSzVyPUG3Ok43OSCwTR?=	MXHTRW5ITVJ?
Saos-2	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULBT2hvUUN3ME2xO\|kvOzVibl2=	NY\2NHlqW0GQR1XS
DK-MG	NIjqSZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXYPWdKSzVyPUG4NE4{KG6P	NUC5UI5XW0GQR1XS
SNU-C2B	NEjDboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPMO\|M6UUN3ME2xPFAvPzNibl2=	NEG2PVdUSU6JRWK=
A427	NXnSb29oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1O5VWlEPTB;MUiyMlU4KG6P	MXfTRW5ITVJ?
KP-N-YS	MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLyTWM2OD1zOEWgcm0>	M3vpdnNCVkeHUh?=
J82	MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzETWM2OD1zOEWuNVghdk1?	NEnBcG1USU6JRWK=
LS-411N	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LV[WlEPTB;MUi3MlI5KG6P	NIT0OHBUSU6JRWK=
HCC1937	M{DXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYr5cY9PUUN3ME2xPFcvPDlibl2=	MVjTRW5ITVJ?
OE33	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfzNJN{UUN3ME2xPFgvQTdibl2=	MVfTRW5ITVJ?
NB7	M1vMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmG0TWM2OD1zOEmuPFkhdk1?	M1nCN3NCVkeHUh?=
SW684	NEjQUVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\GVlRvUUN3ME2xPVYvOTNibl2=	M3z1PHNCVkeHUh?=
HT-144	NEHpOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2C2RmlEPTB;MUm2MlE2KG6P	NGTONXNUSU6JRWK=
SK-MEL-30	NIrLXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\xTWM2OD1zOU[uNkBvVQ>?	NGTiSGhUSU6JRWK=
DBTRG-05MG	NILlbVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjDfldKSzVyPUG5PE41PyCwTR?=	M2PrN3NCVkeHUh?=
NCI-H1395	NFnSWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTF7OD64OUBvVQ>?	NXq5TWw6W0GQR1XS
NCI-H2122	NHj4b4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTYTWM2OD1{MECuOVkhdk1?	NFjhNolUSU6JRWK=
no-10	NXz6e\|dST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2X2OWlEPTB;MkCxMlA1KG6P	NVXQeWtDW0GQR1XS
SW48	M1Wzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTtXItKSzVyPUKwNU4{OSCwTR?=	NV;acIdWW0GQR1XS
NCI-H1650	NEf4dXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjaWXlKSzVyPUKwOE4xOSCwTR?=	NV\tenBwW0GQR1XS
MZ1-PC	MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LqVmlEPTB;MkC1MlU5KG6P	MWfTRW5ITVJ?
U-266	NEjxXYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fqeGlEPTB;MkC1Mlc6KG6P	NIfOdmVUSU6JRWK=
CAS-1	NIHkO\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3KVItKSzVyPUKwO{41PCCwTR?=	MoroV2FPT0WU
AU565	Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fuXGlEPTB;MkGyMlgzKG6P	NYnLeIlpW0GQR1XS
UACC-257	MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXuTWM2OD1{MUOuPVkhdk1?	MWPTRW5ITVJ?
CAL-27	MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M164cGlEPTB;MkG3MlA2KG6P	M{DvUnNCVkeHUh?=
NCI-H23	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3NbHd7UUN3ME2yNVkvOzNibl2=	M1jOeHNCVkeHUh?=
TE-6	M3rodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjvV5JzUUN3ME2yNVkvPjhibl2=	MVPTRW5ITVJ?
TGBC24TKB	Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGL6Z\|ZKSzVyPUKyNk4yPyCwTR?=	NE\6Z\|RUSU6JRWK=
TE-1	NF25T3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjnWm1KSzVyPUKyNk45QCCwTR?=	NHnCNlFUSU6JRWK=
RCC10RGB	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7vVYlqUUN3ME2yNlQvOTlibl2=	NHrsWmFUSU6JRWK=
NCI-H596	NEjvdGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYj6bpQ{UUN3ME2yNlgvOjJibl2=	NYDBOmhbW0GQR1XS
SW954	M2TBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHMWW95UUN3ME2yN\|MvQDNibl2=	M2HLS3NCVkeHUh?=
NCI-H2087	MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTJ\|ND61NUBvVQ>?	MmjxV2FPT0WU
SK-PN-DW	MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fFXWlEPTB;MkO1MlE6KG6P	Ml7nV2FPT0WU
KM12	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nCeGlEPTB;MkO1Mlchdk1?	NX3VVFU{W0GQR1XS
BT-474	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLjTWM2OD1{M{WuO\|Mhdk1?	MWLTRW5ITVJ?
IST-MES1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TvbGlEPTB;MkO2MlU4KG6P	MVPTRW5ITVJ?
HT-1197	NXnrS5lnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTJ\|OD6wPUBvVQ>?	M{juOXNCVkeHUh?=
CAL-54	Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHKcG1KSzVyPUKzPE41QSCwTR?=	M4XSSHNCVkeHUh?=
NB10	M1jJT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3n4[2lEPTB;MkSwMlA3KG6P	MX7TRW5ITVJ?
PANC-10-05	M134[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXRTWM2OD1{NEWuOVYhdk1?	MV;TRW5ITVJ?
NCI-H522	NH\YU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXvz[nY1UUN3ME2yOFgvOzFibl2=	MYrTRW5ITVJ?
A388	M1zBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDNTpo4UUN3ME2yOFkvQDJibl2=	Mmm5V2FPT0WU
GOTO	Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTJ3MD6yPUBvVQ>?	MmToV2FPT0WU
KLE	NYrpUIpKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTSS3ZRUUN3ME2yOVEvQDdibl2=	NFXDXm5USU6JRWK=
KYSE-520	NGDzVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTJ3Mj64OkBvVQ>?	MYfTRW5ITVJ?
HCE-4	MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoCwTWM2OD1{NkKuOUBvVQ>?	M{L2UnNCVkeHUh?=
KURAMOCHI	NWXVWpNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LvdWlEPTB;Mk[1Mlkhdk1?	NGnXeW9USU6JRWK=
HCC38	NUnkU4dPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTJ4Nj60PEBvVQ>?	M1T1e3NCVkeHUh?=
FADU	M3nsU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTJ4Nj62N{BvVQ>?	MkL1V2FPT0WU
CW-2	NYLX[FBZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13WV2lEPTB;Mk[5Mlk3KG6P	NFn5dlJUSU6JRWK=
L-428	NIXHdYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTp[HFWUUN3ME2yO\|UvOTVibl2=	MUPTRW5ITVJ?
HCC1569	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofqTWM2OD1{N{WuPFQhdk1?	M37jWXNCVkeHUh?=
NCI-H810	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2iy[2lEPTB;Mke4MlMyKG6P	MX3TRW5ITVJ?
LB771-HNC	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknhTWM2OD1{OEWuPFQhdk1?	NWfTdnNpW0GQR1XS
LCLC-103H	M4\XW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPTeGRKSzVyPUK4OU46QSCwTR?=	M3HiSnNCVkeHUh?=
EFO-21	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3K1VmlEPTB;Mki3MlY5KG6P	M{DEfnNCVkeHUh?=
CAL-72	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLTSHFOUUN3ME2yPVMvOTlibl2=	M{PzN3NCVkeHUh?=
SCC-9	M2TjRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLmW\|VKSzVyPUK5N{4zOiCwTR?=	NWrWTZZNW0GQR1XS
COLO-829	NVrtS\|lFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULPZnBwUUN3ME2yPVYvPSCwTR?=	M3nPS3NCVkeHUh?=
U-87-MG	MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYf3cpQ2UUN3ME2zNFAvPzNibl2=	MYnTRW5ITVJ?
MZ7-mel	M4Pxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTN{Mz63OkBvVQ>?	MkDmV2FPT0WU
NCI-H1770	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\aTWM2OD1\|Mk[uO\|Qhdk1?	NVrPfIRQW0GQR1XS
ChaGo-K-1	NW\NT\|l7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTN{OD6xJI5O	Mo[wV2FPT0WU
SiHa	M2jzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fBZ2lEPTB;M{K5MlI1KG6P	NVjUSphCW0GQR1XS
NCI-SNU-5	NFTsW4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTN\|Nj63O{BvVQ>?	MmrQV2FPT0WU
DJM-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mon4TWM2OD1\|NECuN\|Mhdk1?	NYrwW2NsW0GQR1XS
OE19	M4rD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TlOWlEPTB;M{SwMlU{KG6P	Mlq2V2FPT0WU
NCI-H1651	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jKNGlEPTB;M{S0MlE5KG6P	MY\TRW5ITVJ?
COLO-792	NIe5WG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjaSJJKSzVyPUO1OE41OiCwTR?=	NWrIRW9iW0GQR1XS
ACHN	M1TWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\EemQ1UUN3ME2zOVYvPzFibl2=	NWr3SJlbW0GQR1XS
TH-3	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1f1eWlEPTB;M{e5Mlk2KG6P	NEWwbIhUSU6JRWK=
HT-1376	M4fOZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXpTWM2OD1\|OESuPFghdk1?	NEfFVYJUSU6JRWK=
RH-18	NWDUcHA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXETWM2OD1\|OUSuO\|Qhdk1?	MVPTRW5ITVJ?
NB6	NGTXd\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoP1TWM2OD1\|OU[uOlYhdk1?	MW\TRW5ITVJ?
COLO-320-HSR	NVHjOoRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33Xb2lEPTB;NECzMlM4KG6P	MoLiV2FPT0WU
UACC-893	NF\1bolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoP6TWM2OD12ME[uOFchdk1?	NYTVbWNbW0GQR1XS
DSH1	NUS0dotiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DRTGlEPTB;NEC2MlkyKG6P	M2juRnNCVkeHUh?=
TE-10	NHHFNItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTRyNz6wNUBvVQ>?	MXXTRW5ITVJ?
HCC70	MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfmfpR2UUN3ME20NFkvOjFibl2=	MYrTRW5ITVJ?
TGBC11TKB	NHPPRYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUi2cVA{UUN3ME20NVAvOzNibl2=	MmTGV2FPT0WU
NCI-H727	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTRzMj6xNUBvVQ>?	MnXyV2FPT0WU
ALL-PO	NEGxWYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTRzNT62PUBvVQ>?	NYj3cIRwW0GQR1XS
ABC-1	NFm0dnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTR{MD60OUBvVQ>?	M{ewUnNCVkeHUh?=
NCI-H69	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHK4ZYJKSzVyPUSyOk44PiCwTR?=	NXvmXWxIW0GQR1XS
GP5d	M4jNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrsTWM2OD12M{SuOFEhdk1?	NGXpZYhUSU6JRWK=
UMC-11	M3u5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDRWVFOUUN3ME20OVgvOzZibl2=	NV2xdYNSW0GQR1XS
RMG-I	Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\vd5dFUUN3ME20OlcvPTZibl2=	MVvTRW5ITVJ?
YAPC	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\kWpk2UUN3ME20PVAvPiCwTR?=	NGPtUnBUSU6JRWK=
LS-1034	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTR7MT6wOkBvVQ>?	NUDzWZQ5W0GQR1XS
RCM-1	MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\VTWM2OD12OU[uOlghdk1?	MoriV2FPT0WU
HCC1954	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTVzMj61JI5O	MYfTRW5ITVJ?
SK-MEL-24	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTVzNj61NUBvVQ>?	Ml32V2FPT0WU
NB12	NGLSb2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXezPW5KUUN3ME21NlgvPDJibl2=	MWLTRW5ITVJ?
SW756	NH;sSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTV3ND65OkBvVQ>?	NGHVdoZUSU6JRWK=
HCC1187	NFe0ZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTV5NT64N{BvVQ>?	M2[3d3NCVkeHUh?=
NCI-H2342	NU[5O5ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfYSoRKSzVyPUW5NE4{QSCwTR?=	MXHTRW5ITVJ?
NCI-H2291	M{XYXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jlN2lEPTB;NUm4MlMyKG6P	NYTHN2ZCW0GQR1XS
OVCAR-3	Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTV7OD65OkBvVQ>?	MUPTRW5ITVJ?
MHH-NB-11	NIfF[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTZ{OT6wNUBvVQ>?	M3LyOXNCVkeHUh?=
SAS	MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37TZ2lEPTB;NkWyMlY4KG6P	NVi4cFBOW0GQR1XS
COLO-824	NXn1U41KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXmVmtLUUN3ME22PFkvOzdibl2=	NGPxS5pUSU6JRWK=
HCC1395	MoKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDr[lNLUUN3ME22PVgvPSCwTR?=	MlHNV2FPT0WU
COLO-668	NE\B[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1X2TWlEPTB;N{C2MlEhdk1?	MWDTRW5ITVJ?
NCI-H226	NITFeZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{G4VWlEPTB;N{C3Mlghdk1?	NEmweW5USU6JRWK=
NB17	M2K2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXLVYNtUUN3ME23NlEvPzVibl2=	MUjTRW5ITVJ?
SW1463	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTd\|OT6xPUBvVQ>?	NXS3VWFDW0GQR1XS
TGW	MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NES3SmpKSzVyPUe2NE4yPSCwTR?=	MX3TRW5ITVJ?
NCI-H526	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTh{Mz61N{BvVQ>?	MnvhV2FPT0WU
COR-L88	NYH1WVI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlT1TWM2OD16NEiuNVIhdk1?	MoS4V2FPT0WU
NCI-H441	NEnaRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTh7NT6yNkBvVQ>?	NHrLXm9USU6JRWK=
NCI-H630	Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIG1cGlKSzVyPUmxNk46PiCwTR?=	NHjpRo1USU6JRWK=
Mo-T	NIHSO\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfjTnJKSzVyPUm0O{45QCCwTR?=	NVnHOJJ{W0GQR1XS
JAR	NWS3S4UzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIOxcIRKSzVyPUm1Ok4zPCCwTR?=	NIPvcpJUSU6JRWK=
NCI-H1838	NHnKe3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HBSmlEPTB;MT6wNlM5QCEQvF2=	NFXwZplUSU6JRWK=
DoTc2-4510	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTFwMEezO\|Yh\|ryP	NVKwTJJWW0GQR1XS
MKN28	NVnsVWpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTFwMEmwNlQh\|ryP	M2n5VnNCVkeHUh?=
HuP-T3	NGDWfnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TWXGlEPTB;MT6xNVkxPSEQvF2=	NIKzV\|RUSU6JRWK=
TE-9	M1vPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXpfGJKSzVyPUGuNVI6PzNizszN	MkPSV2FPT0WU
NY	MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYKyUHkxUUN3ME2xMlE3Pzl{IN88US=>	MmLqV2FPT0WU
HT55	M3zPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\Se2lEPTB;MT6zNVM1PCEQvF2=	Mn31V2FPT0WU
SW837	M1vpU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXjenBKSzVyPUGuN\|I6PzhizszN	NWC5e2k6W0GQR1XS
NCI-H2029	Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XlSGlEPTB;MT60NVc6OSEQvF2=	NHHtSnhUSU6JRWK=
IST-SL1	NIK0RYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTFwNESyOEDPxE1?	NV;MS5U6W0GQR1XS
COLO-741	MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTFwNEm3O\|Eh\|ryP	MVrTRW5ITVJ?
LU-65	NEK3WXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVr0XpNZUUN3ME2xMlYzOjR7IN88US=>	MnuzV2FPT0WU
NCI-H1304	NFjTXYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGf0elFKSzVyPUGuOlU1QThizszN	MkTaV2FPT0WU
KARPAS-299	NXLoNYV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDV[4lKSzVyPUGuO\|k1PzlizszN	NIHCU4RUSU6JRWK=
NCI-H358	NVezcIN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTFwOUW1NFMh\|ryP	M1[xeHNCVkeHUh?=
OAW-28	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTJwME[5NVkh\|ryP	MmfCV2FPT0WU
C8166	M4\vSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTJwNkOzPVIh\|ryP	NX7Md\|hrW0GQR1XS
COLO-678	M1HuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHuOolDUUN3ME2yMlg{PzZ6IN88US=>	NFzHRWpUSU6JRWK=
SK-N-DZ	MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI[xOGlKSzVyPUKuPFY{QDFizszN	M{TSRXNCVkeHUh?=
NCI-H82	NVXTS3h4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHuXVY3UUN3ME2yMlkxOzZ7IN88US=>	NH;1eVVUSU6JRWK=
JVM-2	MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XTbGlEPTB;Mz6wN\|E5QCEQvF2=	NHnrbmZUSU6JRWK=
SW1116	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTNwMEW0NVEh\|ryP	M2XJcHNCVkeHUh?=
MDA-MB-453	NYLzenJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnlTWM2OD1\|LkGwOFM6KM7:TR?=	MXjTRW5ITVJ?
Calu-6	NVjOVJJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY[4[\|FxUUN3ME2zMlE6QTdizszN	NFHGcolUSU6JRWK=
SHP-77	M{jTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmj3TWM2OD1\|LkWyPEDPxE1?	NYTNc3VFW0GQR1XS
Capan-2	NXvYNo5XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjSbGlGUUN3ME20MlMzPThzIN88US=>	NFLHW3dUSU6JRWK=
SW948	NIqxOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3HTWM2OD12Lke0O\|c6KM7:TR?=	MWHTRW5ITVJ?
HDLM-2	M1zIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTveVlIUUN3ME21MlA4PzJ3IN88US=>	MXrTRW5ITVJ?
LAN-6	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TvR2lEPTB;Nj6yNVQ6PSEQvF2=	M3jZTnNCVkeHUh?=
LU-135	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTEemJjUUN3ME22MlQ{ODd5IN88US=>	NXz0eVFoW0GQR1XS
T84	M3zWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHL6WHBKSzVyPU[uPVg3PCEQvF2=	M3TsdHNCVkeHUh?=
CAPAN-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFP5c25KSzVyPUeuOlIzOzNizszN	NWLTcpMzW0GQR1XS
SW1417	MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTdwOUG3N\|Eh\|ryP	NIn1NHdUSU6JRWK=
BALL-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRThwNUC0NFkh\|ryP	NF22V\|JUSU6JRWK=
HT-29	M3fiSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH33TW9KSzVyPUmuNFc2QTlizszN	MW\TRW5ITVJ?
C3A	M2TPWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTlwOEizPVQh\|ryP	MVrTRW5ITVJ?
NCI-H1993	NYruPG5lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmr0TWM2OD1zMD61NFgyKM7:TR?=	NYPGR3FTW0GQR1XS
SK-MEL-1	NWHwboRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTFzLk[yPFkh\|ryP	MY\TRW5ITVJ?
DU-145	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLjTFExUUN3ME2xOE42ODV{IN88US=>	NGX4eYlUSU6JRWK=
KP-N-YN	M4fke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjMZXhlUUN3ME2xOE42OTB\|IN88US=>	NILJO4lUSU6JRWK=
CCRF-CEM	NWDIO2ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTF2Lke4NFkh\|ryP	NYnZeolCW0GQR1XS
ZR-75-30	NEXyXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmeyTWM2OD1zNj6zN\|A{KM7:TR?=	NX3RWlhNW0GQR1XS
A673	M3fIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NISwN\|VKSzVyPUKwMlU2ODdizszN	NWPZVHYyW0GQR1XS
K-562	MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH35bIlKSzVyPUK4MlQyQDNizszN	NVXCWYUxW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo

BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies. ^[1]

Protocol

Kinase Assay: ^[1]	+ Expand In vitro Protein Kinase, PI3K, and mTOR Assays: PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH₂-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.
Cell Research: ^[2]	+ Expand Cell lines: HCT116, DLD-1 and SW480 cells Concentrations: 0-1 μM Incubation Time: 48 hours Method: The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. Cells are plated at different initial densities (HCT116: 3 × 10³ cells/well, DLD-1: 5.5 × 10³ cells/well, SW480: 4.5 × 10³ cells/well, DLD-1 PIK3CA mutant: 7 × 10³ cells/well, and DLD-1 PIK3CA wild-type: 9 × 10³ cells/well) to account for differential growth kinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235, and the drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after the initial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay, as per the manufacturer's instructions. Cell viability after drug treatment is normalized to that of untreated cells also grown for 48 hours. For western blot analysis, cells are plated with zero or maximum inhibitory dose (500 nM) BEZ235 for 2, 6, 24, or 48 hours. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: Female Harlan athymic nude mice Formulation: NMP/polyethylene glycol 300 (10/90, v/v) Dosages: 45 mg/kg Administration: p.o. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMF	18 mg/mL warmed (38.33 mM)
	DMSO	0.01 mg/mL (0.02 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): NMP+polyethylene glycol 300 (10+90, v+v) For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Molecular Weight	469.55
Formula	C₃₀H₂₃N₅O
CAS No.	915019-65-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03373903	Active not recruiting	Respiratory Tract Infections	Restorbio Inc.	November 15 2017	Phase 2
NCT03373903	Active not recruiting	Respiratory Tract Infections	Restorbio Inc.	November 15 2017	Phase 2
NCT01856101	Terminated	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01856101	Terminated	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01717898	Terminated	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2
NCT01717898	Terminated	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
With difficulties in dissolving BEZ235, How can I improve its solubility?
Answer:
For in vivo study, we suggest the vehicle solution NMP/polyethylene glycol 300 (10/90, v/v). Please dissolve BEZ235 in NMP as more as possible. You can sonicate and warm it in water bath for a while. Then dilute with PEG 300.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Selective PI3K Inhibitors

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
Selective PI3K Inhibitors

TGX-221 : p110β-specific, IC50=5 nM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products5

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Buparlisib (BKM120, NVP-BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235, NVP-BEZ235)

Cited by 88 Publications

11 Customer Reviews

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235, NVP-BEZ235)

Cited by 88 Publications

11 Customer Reviews

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Dactolisib (BEZ235, NVP-BEZ235) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)